[go: up one dir, main page]

MX2007015171A - Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable. - Google Patents

Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable.

Info

Publication number
MX2007015171A
MX2007015171A MX2007015171A MX2007015171A MX2007015171A MX 2007015171 A MX2007015171 A MX 2007015171A MX 2007015171 A MX2007015171 A MX 2007015171A MX 2007015171 A MX2007015171 A MX 2007015171A MX 2007015171 A MX2007015171 A MX 2007015171A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
formulation
acceptable surfactant
farnesyl dibenzodiazepinone
preparation
Prior art date
Application number
MX2007015171A
Other languages
English (en)
Inventor
Maxime Ranger
Original Assignee
Thallion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thallion Pharmaceuticals Inc filed Critical Thallion Pharmaceuticals Inc
Publication of MX2007015171A publication Critical patent/MX2007015171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invencion se refiere a formulaciones farmaceuticas que comprenden un compuesto de dibenzodiazepinona farnesilo, o un analogo, o una sal farmaceuticamente aceptable o profarmaco del mismo, y un agente tensoactivo farmaceuticamente aceptable y que tiene propiedades biologicas y quimicas mejoradas. Tal formulacion es una solucion lista para utilizarse adecuada para la administracion parenteral o no parenteral o una formulacion voluminosa para preparacion extemporanea. La presente invencion tambien se refiere a metodos terapeuticos que utilizan las formulaciones, y metodos para su preparacion.
MX2007015171A 2005-06-02 2006-05-30 Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable. MX2007015171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68639405P 2005-06-02 2005-06-02
PCT/CA2006/000884 WO2006128288A1 (en) 2005-06-02 2006-05-30 Formulation comprising farnesyl dibenzodiazepinone and a pharmaceutically acceptable surfactant

Publications (1)

Publication Number Publication Date
MX2007015171A true MX2007015171A (es) 2008-04-22

Family

ID=36930116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015171A MX2007015171A (es) 2005-06-02 2006-05-30 Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable.

Country Status (7)

Country Link
US (1) US20060276436A1 (es)
EP (1) EP1898920A1 (es)
JP (1) JP2008542308A (es)
AU (1) AU2006254675A1 (es)
CA (1) CA2547866C (es)
MX (1) MX2007015171A (es)
WO (1) WO2006128288A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005289317A1 (en) * 2004-09-27 2006-04-06 Thallion Pharmaceuticals Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
WO2007038512A2 (en) * 2005-09-27 2007-04-05 Thallion Pharmaceuticals Inc. Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals
WO2009124399A1 (en) * 2008-04-11 2009-10-15 Thallion Pharmaceuticals Inc. Inhibition of cell migration by a farnesylated dibenzodiazepinone
JP7378155B2 (ja) * 2017-10-27 2023-11-13 エーエムオー ファーマ リミテッド ファルネシルジベンゾジアゼピノンを使用してフェラン・マクダーミド症候群を処置する方法
GEP20247606B (en) * 2018-11-27 2024-03-11 Bayer Ag Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CA3098177A1 (en) * 2020-10-30 2022-04-30 Emory University Modulators of orphan nuclear receptors for use in treating pancreatitis, glioblastoma, sarcopenia, stroke, and traumatic brain injury

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5039660A (en) * 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
DK0612521T3 (da) * 1991-11-11 2000-01-17 Hisamitsu Pharmaceutical Co Keterolacholdigt varmt omslag
US5541181A (en) * 1994-05-26 1996-07-30 Bristol-Myers Squibb Company Compound produced by a strain of micromonospora
US5914342A (en) * 1995-06-07 1999-06-22 The Procter & Gamble Company 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US7186713B2 (en) * 2003-01-21 2007-03-06 Ecopia Biosciences, Inc. Farnesyl dibenzodiazepinones and methods of treating cancer using same
CA2466340C (en) * 2003-01-21 2007-07-10 Ecopia Biosciences Inc. Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
AU2005289317A1 (en) * 2004-09-27 2006-04-06 Thallion Pharmaceuticals Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals

Also Published As

Publication number Publication date
JP2008542308A (ja) 2008-11-27
CA2547866C (en) 2008-08-12
EP1898920A1 (en) 2008-03-19
US20060276436A1 (en) 2006-12-07
AU2006254675A1 (en) 2006-12-07
CA2547866A1 (en) 2006-08-22
WO2006128288A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
PT2038290E (pt) Moduladores de receptor do tipo toll 7
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2012054500A3 (en) Compositions for drug administration
TW200640908A (en) Chemical compounds
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
WO2006124447A3 (en) Substituted n-arylpyrrolidines as selective androgen receptor modulators
TN2013000257A1 (en) Immunosuppressant formulations
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
WO2008006795A3 (en) Indole compounds
TW200806291A (en) Pharmaceutical formulations
MX2009005368A (es) Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.
TW200626553A (en) Novel compounds
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2007015171A (es) Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable.
WO2008004100A9 (en) Therapeutic compounds
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
TW200800984A (en) New compounds
WO2007121471A3 (en) Dialkyl ether delivery agents
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal